ClinicalTrials.gg
CompletedNCT00254202Updated Oct 6, 2026Results posted

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

A Phase 3 interventional study of Iloperidone and Ziprasidone in Schizophrenia, sponsored by Vanda Pharmaceuticals. Completed at 42 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Oct 6, 2026Posted results revised3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
593
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.

Enrollment
2nd of 11
593 · median 260
Started
2005
the only one that year
Phase 3
4 of 11
1 open now
Registered
1st of 11
by date
Lead sponsor
7 of 11
Vanda Pharmaceuticals

Among the 11 studies testing iloperidone in Schizophrenia, this one is the 2nd largest by enrollment, is the only one that started in 2005, is one of 4 in phase 3, and was the 1st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About iloperidone

iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing iloperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.

Read the detailed description

Schizophrenia is a severe mental illness affecting an estimated 1% of the world's population. Patients with schizophrenia suffer from productive symptoms (e.g., hallucinations and delusions), and deficit symptoms (e.g., a reduction or absence of normal behaviors or emotions). Other symptoms include a reduced ability to recall and learn new information.

Iloperidone is being development as a treatment for symptoms of schizophrenia. This trial will test the safety and efficacy of iloperidone in patients with an acute exacerbation of the disease.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Atypical antipsychotic
  • Psychosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of schizophrenia
  • PANSS-T of at least 70 at screening and baseline

Exclusion criteria

Exclusion Criteria:

  • disease of the heart, kidneys, liver or gastrointestinal system
  • diagnosis of psychiatric disorder other than schizophrenia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
593 participants (actual)

Study arms

  • Experimental
    Iloperidone

    Oral iloperidone

    Drug: Iloperidone

  • Active comparator
    Ziprasidone

    Oral ziprasidone

    Drug: Ziprasidone

  • Placebo comparator
    Placebo

    Oral placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score

    The PANSS is a 30-item scale developed to assess the severity of symptoms of schizophrenia. The PANSS items are divided into positive, negative, and general psychopathology factors. Items are rated on a scale of 1 (absent) to 7 (extremely severe). The PANSS-T score is the sum of scores for all 30 PANSS items (i.e., the sum of the three subscales), with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. A negative change from baseline indicates improvement.

    Time frame: 4 weeks

07

Results

Posted Dec 13, 2024

Participant flow

Participant flow — Overall Study
MilestoneIloperidoneZiprasidonePlacebo
Started295149149
Safety population300150147
Completed1939890
Not completed1025159

Outcome measures

PrimaryChange From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score

The PANSS is a 30-item scale developed to assess the severity of symptoms of schizophrenia. The PANSS items are divided into positive, negative, and general psychopathology factors. Items are rated on a scale of 1 (absent) to 7 (extremely severe). The PANSS-T score is the sum of scores for all 30 PANSS items (i.e., the sum of the three subscales), with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. A negative change from baseline indicates improvement.

Time frame:
4 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score
score on a scaleIloperidoneZiprasidonePlacebo
Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score-12.0 ± 1.03-12.3 ± 1.44-7.1 ± 1.48

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iloperidone0/300 (0%)2/300 (0.7%)221/300 (73.7%)
Ziprasidone0/150 (0%)2/150 (1.3%)118/150 (78.7%)
Placebo0/147 (0%)5/147 (3.4%)86/147 (58.5%)
Most frequent serious events
Most frequent serious events
EventIloperidoneZiprasidonePlacebo
ConvulsionNervous system disorders0/3000/1502/147
Psychotic disorderPsychiatric disorders1/3002/1500/147
BradycardiaCardiac disorders0/3000/1501/147
Chest painGeneral disorders0/3000/1501/147
Myocardial infarctionCardiac disorders0/3000/1501/147
HyponatremiaMetabolism and nutrition disorders0/3000/1501/147
SchizophreniaPsychiatric disorders0/3000/1501/147
Microcytic anemiaBlood and lymphatic system disorders1/3000/1500/147
Most frequent other events
Showing 10 of 25
Most frequent other events
EventIloperidoneZiprasidonePlacebo
SedationNervous system disorders38/30041/15012/147
HeadacheNervous system disorders61/30035/15029/147
DizzinessNervous system disorders51/30020/15011/147
NauseaGastrointestinal disorders29/30021/15013/147
Weight increasedInvestigations34/3007/1503/147
VomitingGastrointestinal disorders17/30016/15010/147
DyspepsiaGastrointestinal disorders24/30015/15015/147
ConstipationGastrointestinal disorders27/30012/15014/147
TachycardiaCardiac disorders28/3003/1501/147
Extrapyramidal disorderNervous system disorders10/30014/1503/147

Baseline characteristics

Age, Continuous
Age, Continuous(years)IloperidoneZiprasidonePlaceboTotal
Mean39.5 ± 10.440.0 ± 9.940.7 ± 10.439.9 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)IloperidoneZiprasidonePlaceboTotal
Female503635121
Male245113114472
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IloperidoneZiprasidonePlaceboTotal
American Indian or Alaskan Native2013
Asian25121552
Black or African American1477676299
Native Hawaiian or Other Pacific Islander2002
White1115146208
Other8101129
08

Study locations

42 sites
  • Vanda Investigational Site
    Little Rock, Arkansas 72211, United States
  • Vanda Investigational Site
    Anaheim, California 92805, United States
  • Vanda Investigational Site
    Cerritos, California 90703, United States
  • Vanda Investigational Site
    Garden Grove, California 92845, United States
  • Vanda Investigational Site
    Glendale, California 91206, United States
  • Vanda Investigational Site
    Los Angeles, California 90048, United States
  • Vanda Investigational Site
    National City, California 91950, United States
  • Vanda Investigational Site
    Oceanside, California 92056, United States
  • Vanda Investigational Site
    Paramount, California 90723, United States
  • Vanda Investigational Site
    Pico Rivera, California 90660, United States
  • Vanda Investigational Site
    San Diego, California 92123, United States
  • Vanda Investigational Site
    San Diego, California 92126, United States
  • Vanda Investigational Site
    San Diego, California 92161, United States
  • Vanda Investigational Site
    Santa Ana, California 92705, United States
  • Vanda Investigational Site
    Upland, California 91786, United States
  • Vanda Investigational Site
    Bradenton, Florida 34208, United States
  • Vanda Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • Vanda Investigational Site
    Maitland, Florida 32751, United States
  • Vanda Investigational Site
    Atlanta, Georgia 30308, United States
  • Vanda Investigational Site
    Augusta, Georgia 30912, United States
  • Vanda Investigational Site
    Hoffman Estates, Illinois 60194, United States
  • Vanda Investigational Site
    Lake Charles, Louisiana 70601, United States
  • Vanda Investigational Site
    Rockville, Maryland 20850, United States
  • Vanda Investigational Site
    Saint Charles, Missouri 63301, United States
  • Vanda Investigational Site
    St Louis, Missouri 63118, United States
  • Vanda Investigational Site
    Clementon, New Jersey 08021, United States
  • Vanda Investigational Site
    Brooklyn, New York 11203, United States
  • Vanda Investigational Site
    Cincinnati, Ohio 45267, United States
  • Vanda Investigational Site
    Philadelphia, Pennsylvania 19131, United States
  • Vanda Investigational Site
    Austin, Texas 78756, United States
  • Vanda Investigational Site
    Houston, Texas 77057, United States
  • Vanda Investigational Site
    Irving, Texas 75062, United States
  • Vanda Investigational Site
    Richmond, Virginia 23229, United States
  • Vanda Investigational Site
    Tirupati, Andhra Pradesh 517507, India
  • Vanda Investigational Site
    Ahmedabad, Gujarat 380006, India
  • Vanda Investigational Site
    Manipal, Karnataka 576104, India
  • Vanda Investigational Site
    Aurangabad, Maharashtra 431005, India
  • Vanda Investigational Site
    Pune, Maharashtra 411001, India
  • Vanda Investigational Site
    Jaipur, Rajasthan 302004, India
  • Vanda Investgational Site
    Chennai, Tamil Nadu 600003, India
  • Vanda Investigational Site
    Lucknow, Uttar Pradesh 226003, India
  • Vanda Investigational Site
    Chinawaltair, Visakha Patnam 530002, India
09

References and documents

Publications

  • Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce. PubMed 18334909 ↗
  • Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry. 2009 Jun;70(6):801-9. doi: 10.4088/jcp.08m04391. PubMed 19573479 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2005 to primary completion in Sep 2006, 10 months.

Results were first posted in Dec 2024, 18 years 2 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 10 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2005
First posted
Nov 15, 2005
StartActual
Nov 18, 2005
Primary completionActual
Sep 26, 2006
CompletionActual
Mar 21, 2007
Results first posted
Dec 13, 2024
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 6, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (2 India, 1 United States)
  • Vanda Investigational Site · St Louis, United States
  • Vanda Investgational Site · Chennai, India
  • Vanda Investigational Site · Lucknow, India
Show 3 removed
  • Vanda Investigational Site · Saint Louis, United States
  • Vanda Investgational Site · Chennai, India
  • Vanda Investigational Site · Lucknow, India
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Posted results revised
    3 sites added, 3 sites removed
    Show 3 added (2 India, 1 United States)
    • Vanda Investigational Site · St Louis, United States
    • Vanda Investgational Site · Chennai, India
    • Vanda Investigational Site · Lucknow, India
    Show 3 removed
    • Vanda Investigational Site · Saint Louis, United States
    • Vanda Investgational Site · Chennai, India
    • Vanda Investigational Site · Lucknow, India
    + 3 other changes: index terms, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00254202
Responsible party
Sponsor
First posted
Nov 15, 2005
Start date
Nov 18, 2005
Primary completion
Sep 26, 2006
Completion
Mar 21, 2007
Results posted
Dec 13, 2024
Last update
Oct 6, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion